Search

Your search keyword '"Stadler B"' showing total 27 results
Start Over Author "Stadler B" Publisher wiley
27 results on '"Stadler B"'

26. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications.

Author

Dolak W, Schwaighofer H, Hellmich B, Stadler B, Spaun G, Plieschnegger W, Hebenstreit A, Weber-Eibel J, Siebert F, Emmanuel K, Knoflach P, Gschwantler M, Vogel W, Trauner M, and Püspök A

Abstract

Background: Photodynamic therapy (PDT) is a palliative treatment for malignant biliary obstruction., Objective: The objective of this article is to assess the feasibility and safety of this technique., Methods: In this nationwide, retrospective study of prospectively collected clinical data, all patients treated with PDT using polyhematoporphyrin in Austria from March 2004 to May 2013 were included. Feasibility, adverse events, stent patency and mortality rates were investigated., Results: Eighty-eight patients (54 male, 34 female, median age 69 years) underwent 150 PDT procedures at seven Austrian referral centers for biliary endoscopy. The predominant underlying disease was Klatskin tumor (79/88). All PDT procedures were feasible without technical issues. Cholangitis was the most frequent adverse event (21/88). Stent patency was 246 days (95% CI 203-289) median and was significantly longer for metal than for plastic stents (269 vs. 62 days, p  < 0.01). The median survival was 12.4 months (95% CI 9.7-14.9 m) calculated from first PDT and 15.6 months (95% CI 12.3-18.7 m) calculated from initial diagnosis. In patients suffering from biliary tract cancer, Cox regression revealed the number of PDT treatment sessions as the only independent predictor of survival at a multivariate analysis ( p  = 0.048)., Conclusion: PDT using polyhematoporphyrin was feasible and safe in this nationwide analysis. Survival data suggest a benefit of PDT in this unselected real-life patient population. Prospective trials comparing PDT to other palliative treatments will help to define its role in the management of malignant biliary obstruction. The study is registered at ClinicalTrials.gov number: NCT02504957.

Published
2017
Full Text
View/download PDF

27. Anti-IgE in allergic sensitization.

Author

Stadler BM, Rudolf MP, Zürcher AW, Miescher S, and Vogel M

Subjects
Animals, Antibodies, Monoclonal therapeutic use, Autoantibodies genetics, Autoantibodies immunology, Cloning, Molecular, Humans, Vaccines immunology, Autoantibodies therapeutic use, Hypersensitivity, Immediate prevention & control, Immunization, Immunoglobulin E immunology
Abstract

Anti-IgE autoantibodies exist predominantly in the sera of patients with atopic disease. For some time such anti-IgE autoantibodies have been considered a phenomenon that may not be of clinical importance. The cloning of such anti-IgE autoantibodies has eliminated doubts of whether these antibodies exist, but it is still unclear whether such autoantibodies play a pathophysiological role. However, there are ongoing clinical trials that use humanized anti-IgE antibodies for passive immunization of atopic individuals. While this approach may not definitely clarify the role of anti-IgE autoantibodies, it will nevertheless clarify the role of IgE.

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results